ENSYSCE BIOSCIENCES, INC. Debt Instrument, Fair Value Disclosure
ENSYSCE BIOSCIENCES, INC. (ENSC) had Debt Instrument, Fair Value Disclosure of $1.20 million as of 2023-12-31, per its 10-K filed 2024-03-15.
Discontinued › Notes › Debt › Debt Instruments
us-gaap:DebtInstrumentFairValue · last filed 2024-03-15
- 2023-12-31: Debt Instrument, Fair Value Disclosure $1.20M.
- 2022-12-31: Debt Instrument, Fair Value Disclosure $287.77K.
- 2022-09-30: Debt Instrument, Fair Value Disclosure $24.82K.
- 2022-06-30: Debt Instrument, Fair Value Disclosure $29.20K.
| Period end | Debt Instrument, Fair Value Disclosure |
|---|---|
| 2023-12-31 | $1.20M 10-K · filed 2024-03-15 |
| 2022-12-31 | $287.77K 10-K · filed 2024-03-15 |
| 2022-09-30 | $24.82K 10-Q · filed 2022-11-14 |
| 2022-06-30 | $29.20K 10-Q · filed 2022-08-11 |
| 2022-03-31 | $509.19K 10-Q · filed 2022-05-12 |
| 2021-12-31 | $3.30M 10-Q · filed 2022-08-11 |
| 2021-09-30 | $620.72K 10-Q · filed 2021-11-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |